Skip to main content
Retour
Watch Compare

PROVECTUS BIOPHARMACEUTICALS, INC.

Qualité des données : 100%
PVCT
OTC Manufacturing Chemicals
0,05 €
▼ 0,00 € (-6,92%)
6 months return
—
Momentum
Neutral
Net margin
-1615,81%

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)-45,54%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net Margin-1615,81%
Op. Margin-1575,32%

Sécurité

Debt / Equity
N/A
Current Ratio0,04
Interest Coverage-991,90

Valorisation

PE (TTM)
-4,41
En dessous de la moyenne du secteur (-1,50)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -3,33 M

Price History

Tendances Financières

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Surprises de Résultats

EPS
Reported Estimate
Q12012 Q22012 Q32012 Q42012
Reported -0,04 € -0,03 € -0,02 € -0,02 €
Estimate -0,04 € -0,03 € -0,03 € -0,03 €
Surprise -14,29% +9,99% +39,99% +33,33%

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) -45,54% Revenue Growth (3Y) -22,37%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: -1615,81%
Revenue (TTM) 336 108,0 Net Income (TTM) -5,43 M
ROE N/A ROA -950,87%
Gross Margin N/A Operating Margin -1575,32%
Net Margin -1615,81% Free Cash Flow (TTM) -3,33 M
ROIC N/A FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 0,04
Debt / Equity N/A Current Ratio 0,04
Interest Coverage -991,90 Asset Turnover 0,59
Working Capital -6,19 M Tangible Book Value -6,15 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -4,41 · EV/EBITDA: N/A
P/E Ratio -4,41 Forward P/E N/A
P/B Ratio N/A P/S Ratio 71,27
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -13,88%
Market Cap 23,96 M Enterprise Value 23,88 M

Per Share

EPS: -0,01 · FCF/Share: -0,01
EPS (Diluted TTM) -0,01 Revenue / Share 0,00
FCF / Share -0,01 OCF / Share -0,01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 61,24% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 61,24%
SBC-Adj. FCF -4,28 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 336 108,0 617 140,0 557 710,0 989 042,0 —
Net Income -5,43 M -4,73 M -3,10 M -3,55 M -5,54 M
EPS (Diluted) -0,01 -0,01 -0,01 — —
Gross Profit — — — — —
Operating Income -5,29 M -4,53 M -2,90 M -3,43 M -4,67 M
EBITDA — — — — —
R&D Expenses 1,90 M 2,00 M 1,75 M 2,39 M 2,61 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 5 338,0 13 591,0 5 650,0 -163 691,0 961 702,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 697 502,0 1,01 M 1,45 M 2,04 M 3,51 M
Total Liabilities 7,00 M 6,98 M 9,04 M 8,27 M 7,70 M
Shareholders' Equity -6,30 M -5,96 M -7,59 M -6,23 M -4,19 M
Total Debt — — — — —
Cash & Equivalents 251 291,0 307 442,0 76 576,0 21 605,0 682 984,0
Current Assets 567 874,0 976 772,0 1,36 M 1,90 M 3,44 M
Current Liabilities 6,90 M 6,98 M 9,02 M 8,19 M 7,70 M

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -4,4 -1,5
P/B — 1,6
ROE % — -54,7
Net Margin % -1615,8 -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3